← Back to Calendar

Rhythm Pharmaceuticals Q4 2025 Earnings

Rhythm Pharmaceuticals · $RYTM
Standard Review Earnings
Catalyst Date
February 26, 2026
Date Status
46d ago (past)
Review Type
Standard (10 mo)

Live Company Data NGM

Updated 5m ago · Data: FMP
Current Price
$84.39 +45.93%
+$26.56 today
Day: $82.96 – $86.19
Market Cap
N/A
Shares out: 68.29M
Float: 55.45M
52-Week Range
$55.31
$122.20
Current price is at 43% of 52-week range
Avg Volume
838K
Beta
2.14
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $RYTM catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + IMCIVREE acquired HO PDUFA update

Key Notes

Q4 2025 earnings reported February 26, 2026. IMCIVREE Q4 revenue $57.3M (FY2025 $194.8M, +50% YoY). FDA PDUFA March 20, 2026 for acquired hypothalamic obesity (sNDA). EMA CHMP opinion expected Q2 2026. Phase 3 EMANATE topline data expected Q1 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar